Peptide Schedule Research TeamReviewed Apr 202613 Citations
Adjust vial, water, and dose — answer updates live
on a U-100 syringe for a 10mcg dose
Never miss a dose — 10mcg daily, draw 0.00 units on U-100 syringe.
No signup required to use calculator
Sync to any calendar app
MK-677 (Ibutamoren) is an oral growth hormone secretagogue backed by a 2-year RCT in healthy elderly adults. It raises IGF-1 40 to 60 percent without suppressing your natural GH axis. Appetite stimulation and insulin resistance are the main limitations. Research compound, not FDA approved.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 15mg | Daily |
| Aggressive | 25mg | Daily |
MK-677 is not a peptide. It is a non-peptide small molecule taken orally as a capsule or liquid solution. No reconstitution, no syringes, no bacteriostatic water. That simplicity is a big part of its popularity. The most common formats are 25 mg capsules (60 per bottle) and liquid solutions at 25 mg/mL in 30 mL dropper bottles. For capsules, dosing is straightforward. For liquid, 10 mg equals 0.4 mL, 15 mg equals 0.6 mL, and 25 mg equals 1 mL. Use a calibrated oral syringe for accuracy. Take it 30 to 60 minutes before bed on an empty stomach. Food blunts the GH response. Bedtime dosing lets you sleep through the worst of the appetite spike and aligns peak GH release with your natural nocturnal surge. The thing most beginners miss: monitor fasting glucose. Buy a home glucometer. Check before you start and again at weeks 4 and 8. If you're running 25 mg for longer than 8 weeks, add HbA1c at the 12-week mark. This is not optional at 25 mg.
Dosing based on Community dosing consensus from peptide research communities — 20 published references.View all sources →
Cross-check your MK-677 (Ibutamoren) reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.